Navigation Links
Neurocrine Biosciences Presents Elagolix Data
Date:6/16/2009

ogram include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risk associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008 and report on Form 10-Q for the quarter ended March 31, 2009. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Reports First Quarter 2008 Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
7. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
9. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
10. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  Celsion Corporation (NASDAQ: CLSN ... a conference call to discuss its second quarter ... its development programs for ThermoDox®, its proprietary heat-activated ... technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy and ... August 10, 2015. To participate in the call, ...
(Date:8/3/2015)... , Aug. 3, 2015 Immune Pharmaceuticals, Inc. ... Dr. Daniel Teper , will present live at ... 6, 2015 TIME:   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... interactive online event where investors are invited to ask ... presentation hall as well as the association,s "virtual trade ...
(Date:8/3/2015)... 2015  Encision Inc. (PK:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 30, 2015. The Company posted quarterly net ... of $213 thousand, or $(0.02) per share. These results ... net loss of $202 thousand, or $(0.02) per share, ...
Breaking Medicine Technology:Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... announces that a new market research report is ... Outlook for Pharmaceuticals in Central Asia ... for Pharmaceutical Markets in Asia is a unique ... Each report provides individual and highly-detailed analysis of ...
... Reportlinker.com announces that a new market research report ... The Market for Pharmaceuticals in Brazil, Russia, India ... Evaluate the status, opportunities and threats ... China now and in the future. Market forecasts ...
Cached Medicine Technology:Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 2Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia 3Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 2Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 3Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 4Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 5
(Date:8/3/2015)... ... August 03, 2015 , ... Results of a comprehensive ... Healthcare Research and Policy Analysis show widespread support for the U.S. Affordable Care ... or strongly agreed that the controversial law passed in 2010 had “more good ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Ahjumawi Lava Springs, California’s northernmost and among its least visited State Parks. ... water aquifers, whose main outflow is at Ahjumawi Lava Springs, part of the ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... A ... Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last 'For ... in patients. According to the report, the new study showed that harvesting stem cell-rich ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Dignity Health ... Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The new ... this year in the West Valley. , “Dr. Baldwin is an excellent leader ...
(Date:8/3/2015)... ... 2015 , ... Cambia Health Solutions has promoted Scott Powers ... Medicare and Federal Employee Programs (FEP) lines of business. , Government programs ... In this role, Scott is responsible for overseeing the growth, finance and operations ...
Breaking Medicine News(10 mins):Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- When ... a pound, Madeline Mann was the world,s smallest surviving baby. ... title of world,s tiniest infant, weighing in at 0.57 pounds. She ... ventilator in the neonatal intensive care unit at Loyola University Medical ...
... University of Georgia and the Mayo Clinic in Arizona have ... model that mimics 90 percent of human breast and pancreatic ... The vaccine, described this week in the early ... of Sciences , reveals a promising new strategy for treating ...
... MONDAY, Dec. 12 (HealthDay News) -- Breast reconstruction is ... mastectomy, according to a new study. Mastectomy is ... of a breast has implications for the psychological, social ... that reconstruction should be offered," Dr. Marissa Howard-McNatt, an ...
... have created a deck of cards with conversation starters ... parents can use to guide their discussions when talking ... Researchers in the Faculty of Medicine & Dentistry at ... on their findings in a recently published paper in ...
... resistance to brain tumor chemotherapy Glioblastoma multiforme ... human brain tumors that originate in the brain. For ... therapy and chemotherapy with temozolomide. However, many GBMs are ... researchers led by Sameer Agnihotri, at the University of ...
... Reporter , MONDAY, Dec. 12 (HealthDay News) -- An advisory panel ... the Ortho Evra birth control patch carries a higher risk of ... be taken off drug store shelves. The panel, which based ... data, voted 19 to 5 that the benefits of Johnson & ...
Cached Medicine News:Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Scientists develop vaccine that attacks breast cancer in mice 2Health News:Scientists develop vaccine that attacks breast cancer in mice 3Health News:Scientists develop vaccine that attacks breast cancer in mice 4Health News:After Mastectomy, Breast Reconstruction Is Safe for Older Women 2Health News:Researchers develop 'conversation cards' to broach subject of pediatric weight management 2Health News:Researchers develop 'conversation cards' to broach subject of pediatric weight management 3Health News:JCI online early table of contents: Dec. 12, 2011 2Health News:JCI online early table of contents: Dec. 12, 2011 3Health News:JCI online early table of contents: Dec. 12, 2011 4Health News:JCI online early table of contents: Dec. 12, 2011 5Health News:JCI online early table of contents: Dec. 12, 2011 6Health News:JCI online early table of contents: Dec. 12, 2011 7Health News:JCI online early table of contents: Dec. 12, 2011 8Health News:JCI online early table of contents: Dec. 12, 2011 9Health News:FDA Panel Cites Clot Risk From Contraceptive Patch 2
... monitor offers a comprehensive array of features ... pediatric and neonate patients, to magnetic resonance ... is the first MR monitor designed to ... neonate patient monitoring. The new monitor is ...
... specific antigen (PSA) is a serine protease that ... epithelial cells of the acini and ducts. Normal ... 0.1-2.6 ng/mL. Reports have suggested that elevated level ... must useful tumor markers in diagnosis of prostate ...
... in vitro assay for detection of alpha ... is a protein with molecular mass ranging ... concentration in serum is below 9 ng/mL; ... ovarian, testicular and presacral teratocarcinomas, and other ...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
Medicine Products: